We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A phase II study of intra-arterial cisplatin with concurrent radiation and erlotinib for locally advanced head and neck cancer.
- Authors
Rao, Krishna; Kalapurakal, Sini; Chalasani, Pratima; Robinson, Kathy; Malone, James; Clausen, Cathy; Ronen, Ohad; Dhiwakar, Muthuswamy; Shevlin, Bruce; Robbins, K.
- Abstract
Background: Based on the convenient oral dosing of erlotinib and the promising results of biologic therapy, we undertook a phase II study with 21 patients with locally advanced (T3-4) lesions combining radiation with intra-arterial (IA) cisplatin and oral daily erlotinib for a 7-week therapy. Methods: Treatment for the primary tumor and upper neck was given to a total dose of 70 Gy. Chemotherapy with IA cisplatin (150 mg/m) was given on days 1, 8, 15, and 22 concurrently with radiotherapy. During the 7-week treatment period, patients were given erlotinib 150 mg/day. Results: Overall survival is 63 %, and the relapse/persistent disease rate stands at 36.8 %. A total of 15.2 % of serious adverse event was considered related to erlotinib. Conclusion: Our study and several others now demonstrate the feasibility of combining anti-epidermal growth factor receptor (EGFR) therapy with chemoradiation, hint at improved survival outcomes with reduced distant metastatic rates, and suggest that maintenance therapy with anti-EGFR agent may be beneficial.
- Subjects
CISPLATIN; INTRA-arterial injections; QUINAZOLINE; HEAD &; neck cancer treatment; CLINICAL trials; ORAL drug administration
- Publication
Cancer Chemotherapy & Pharmacology, 2013, Vol 72, Issue 3, p545
- ISSN
0344-5704
- Publication type
Article
- DOI
10.1007/s00280-013-2225-7